Samuel Gore

@Ruycorto $RAC Phase 3 Oncology company with their lead asset RC220, a platform pipeline drug and the most developed+most potent silencer of the ‘Holy Grail’ and long time undruggable cancer target MYC. MYC is ~70% of all cancer. Cheap share price compared to company valuations in RAS ;)

Favorite ASX Biotech and Why? Lets Go

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial prn.to/4nurfSC

Announcement: @Racuraoncology has received clearance from the Safety Review Committee (SRC) for our Cardioprotection and Anticancer Synergy (#CPACS) Phase 1 trial, to progress to the next RC220 dose level. More here: announcements.racuraoncology.com/announcements/… #RC220 #clinicaltrial

@Racuraoncology ($RAC) and @UOW have been granted funding under the NSW Government TechVouchers program to study the efficacy of (E,E)-bisantrene in BRCA-mutated breast and ovarian cancers. More here: rac.live.irmau.com/pdf/bc55603c-8… #oncology #eebisantrene #BRCAgene

Yesterday, @Racuraoncology ($RAC) Senior Scientist Dr Sumit Sahni presented a poster at the @AACR Annual Meeting. Sumit presented data demonstrating how lead asset (E,E)-bisantrene silences key cancer driver MYC. More here: announcements.racuraoncology.com/announcements/… #eebisantrene #oncology #myc

This week, @RacuraOncology (ASX:RAC) Senior Scientist Dr Sumit Sahni is pleased to be attending and presenting at the @AACR Research Annual Meeting 2026 in San Diego. More information here: rac.live.irmau.com/pdf/4b1ba410-4… #AACR #cancerresearch

For those who were unable to attend or wish to revisit the presentations, a recording of our recent @RacuraOncology Investor Symposium is now available: youtu.be/lobYnFg5Xkc #Racura #Biotech #CancerCare $RAC

@RacuraOncology ($RAC) announces another trial milestone with third patient dosed with RC220 in CPACS Phase 1 clinical trial in advanced solid tumours, at the first Hong Kong site. More here: announcements.racuraoncology.com/announcements/… #clinicaltrial #solidtumors #CPACS

@RacuraOncology ($RAC) has been invited to present a poster at the @AACR Annual Meeting 2026 in San Diego, 17-22 April. Presentation abstract & ASX release here: rac.live.irmau.com/pdf/4b1ba410-4… #AACR26 #cancerresearch

Watch @StockheadAU's latest Long Shortz video with @tylahtully as she discusses @RacuraOncology's ($RAC) governance approval for the HARNESS-1 lung cancer trial with CEO Dr Daniel Tillett. Watch here: stockhead.com.au/stockhead-tv/l… #clinicaltrial #eebisantrene

@RacuraOncology ($RAC) has received governance approval from @MonashHealth for its RC220 HARNESS-1 Lung Cancer Trial, assessing RC220 (E,E-bisantrene) in combination with osmertinib in patients with non-small cell lung cancer. More here: announcements.racuraoncology.com/announcements/… #eebisantrene

Announcement 📣: @RacuraOncology ($RAC) has commenced a collaboration with @EmoryUniversity to study (E,E)-bisantrene in osimertinib resistant epidermal growth factor receptor mutated non-small cell #LungCancer. More here: announcements.racuraoncology.com/announcements/… #clinicaltrial #bisantrene

Announcement: @RacuraOncology ($RAC) has appointed Beyond Drug Development to support the development of our HARNESS-1 Phase 1a/b clinical trial. More here: rac.live.irmau.com/pdf/368e2cf6-6… #clinicaltrial #biotech

📣 Big News... Race Oncology is now Racura Oncology! Today marks an exciting milestone as we officially become Racura Oncology (ASX:RAC), reflecting $RAC’s strategic evolution and major scientific advancements since our early days as a #biotech start-up. racuraoncology.com

$RAC has raised more than $3.22m in a #PrivatePlacement with existing shareholders to enable to commencement of our Phase 1 lung cancer trial. Recruitment expected in early Q12026. More details here: announcements.raceoncology.com/announcements/… #BestShareholders #OncologyTrials #LungCancer

We’ve released a fireside-style chat with $RAC ’s Board, hosted by Chris Kallos, MST Financial covering: • The Board’s experience & vision • RC220’s clinical potential • The opportunity to bring RC220 forward in a range of potential commercial settings shorturl.at/h1NqS

$RAC secures ethics approval for HARNESS-1 Phase 1a/b #lungcancer trial of RC220 in combination with osimertinib. Trial aimed at treating patients with resistance to 3rd gen EGFRm NSCLC TKIs. More info in this @proactive_au article: shorturl.at/o9M7C

📹 Investor webinar recording now available! For those who missed $RAC’s clinical program update yesterday, detailing 2 new clinical trials in #AML and #NSCLC, you can access the recording here: youtube.com/watch?v=3H3wR5…

🦠Island Pharmaceuticals $ILA receives @FDA confirmation that #Galidesivir qualifies for the Animal Rule pathway and a Priority Review Voucher on approval. FDA guidance de-risks and accelerates the program, w/ trials targeted to begin in Q1 CY26. islandpharmaceuticals.com/site/pdf/cf490… #Marburg

$RAC Race Oncology launches new clinical programs in AML and lung cancer tinyurl.com/24vqpjht @RaceOncology $FN3 $RAONF #RAC #FN3 #RAONF